Grupo para la caracterización molecular de las neoplasias hematológicas
University College London Hospitals NHS Foundation Trust
Londres, Reino UnidoPublikationen in Zusammenarbeit mit Forschern von University College London Hospitals NHS Foundation Trust (2)
2024
-
Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 Study
Clinical Lymphoma, Myeloma and Leukemia, Vol. 24, Núm. 3, pp. 194-202
2023
-
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
New England Journal of Medicine, Vol. 389, Núm. 4, pp. 335-347